- Home
- YI vs BRNS Comparison
YI vs BRNS Comparison
Compare YI & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YI | BRNS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 30.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YI | BRNS |
|---|---|---|
| Price | $3.47 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 6.1K | ★ 54.9K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.48 | $0.51 |
| 52 Week High | $11.17 | $1.83 |
Technical Indicators
Market Signals| Indicator | YI | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 59.44 |
| Support Level | $2.48 | $0.65 |
| Resistance Level | $4.01 | $0.74 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 40.16 | 67.06 |
Price Performance
Historical ComparisonAbout YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.